Clinical Trials Logo

T2DM (Type 2 Diabetes Mellitus) clinical trials

View clinical trials related to T2DM (Type 2 Diabetes Mellitus).

Filter by:

NCT ID: NCT04632862 Completed - Clinical trials for T2DM (Type 2 Diabetes Mellitus)

The Efficacy and Safety of DWP16001 Compared to Placebo in the Treatment of Type 2 Diabetes Mellitus.

Start date: November 11, 2020
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the efficacy and safety of DWP16001 compared to placebo in the treatment of type 2 diabetes mellitus.

NCT ID: NCT03467932 Completed - Clinical trials for T2DM (Type 2 Diabetes Mellitus)

A Study to Evaluate the Efficacy and Safety of ORMD-0801 (Oral Insulin) in Patients With Type 2 Diabetes Mellitus

Start date: May 29, 2018
Phase: Phase 2
Study type: Interventional

This is a four-way (Participant, Care Provider, Investigator, Outcomes Assessor) masked (blinded) study designed to explore the efficacy of ORMD-0801 when given in different regimens across a dose range for up to 12 weeks in subjects with type 2 diabetes mellitus (T2DM).

NCT ID: NCT03437109 Completed - Hypogonadism Clinical Trials

Efficacy of Androgen Substitution for Hypogonadism in Men With Type 2 Diabetes Mellitus

DESTINY
Start date: December 6, 2017
Phase:
Study type: Observational

The purpose of the study is to get data of prevalence of testosterone deficiency in patient with T2DM in Russian Federation

NCT ID: NCT03233178 Completed - NAFLD Clinical Trials

Measurement of Alanine Aminotransaminase (ALT) Following Initiation of Antidiabetic Agents in Patients With Type 2 Diabetes in a Real-world Clinical Setting: a Retrospective Cohort Study

ALT
Start date: January 2017
Phase: N/A
Study type: Observational

The primary objective of this study is to investigate the change in Alanine Aminotransaminase (ALT) in patients with Type 2 Diabetes Mellitus (T2DM) initiating Sodium Glucose Cotransporter 2 (SGLT2) inhibitors, liraglutide, or sitagliptin, compared to a control group of patients who did not initiate a new antihyperglycemic therapy. The hypothesis is that patients using Sodium Glucose Cotransporter 2 inhibitors (SGLT2i) will achieve a greater reduction in ALT compared to the control group.

NCT ID: NCT03155087 Completed - Clinical trials for T2DM (Type 2 Diabetes Mellitus)

PRKAA2 Genetic Polymorphisms and Its Susceptibility to Chinese Type 2 Diabetes Mellitus and Diabetic Nephropathy

Start date: June 2013
Phase: N/A
Study type: Observational

Metformin is a classical oral antidiabetic drug, often recommended to be the first-choice treatment of type 2 diabetes mellitus (T2DM). Based on the previous research on PRKAA2, STK11 and diabetes, this study aimed to investigate the distributive characteristic of PRKAA2 and STK11 polymorphisms and the potential influence of STK11polymorphisms on metformin efficacy among Chinese T2DM patients, discuss the association of PRKAA2 polymorphisms between T2DM patients and healthy subjects.

NCT ID: NCT03050229 Completed - Clinical trials for T2DM (Type 2 Diabetes Mellitus)

SGLT-2i and ARB Combination Therapy in Patients With T2DM and Nocturnal Hypertension (SACRA Study)

Start date: January 2017
Phase: Phase 4
Study type: Interventional

To explore the beneficial effects of 'empagliflozin + ARB' in comparison with 'placebo + ARB' on the reduction of nocturnal blood pressure in T2DM with hypertension

NCT ID: NCT01373814 Completed - Clinical trials for T2DM (Type 2 Diabetes Mellitus)

Nutritional Therapy for Diabetic Cardiomyopathy

Start date: September 3, 2010
Phase:
Study type: Observational

The goal of this study is to determine if nutritional therapy can effectively treat/prevent T2DM and its consequent cardiomyopathy.